vs
Orthofix Medical Inc.（OFIX）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Purple Innovation, Inc.的1.6倍（$219.9M vs $140.7M），Orthofix Medical Inc.净利率更高（-1.0% vs -2.3%，领先1.3%），Purple Innovation, Inc.同比增速更快（9.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-7.8M），过去两年Purple Innovation, Inc.的营收复合增速更高（8.3% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
OFIX vs PRPL — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$140.7M
营收增速更快
PRPL
高出7.1%
2.0%
净利率更高
OFIX
高出1.3%
-2.3%
自由现金流更多
OFIX
多$24.6M
$-7.8M
两年增速更快
PRPL
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $140.7M |
| 净利润 | $-2.2M | $-3.2M |
| 毛利率 | 71.1% | 41.9% |
| 营业利润率 | 0.2% | -1.6% |
| 净利率 | -1.0% | -2.3% |
| 营收同比 | 2.0% | 9.1% |
| 净利润同比 | 92.4% | 62.1% |
| 每股收益（稀释后） | $-0.05 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPRPL
| Q4 25 | $219.9M | $140.7M | ||
| Q3 25 | $205.6M | $118.8M | ||
| Q2 25 | $203.1M | $105.1M | ||
| Q1 25 | $193.6M | $104.2M | ||
| Q4 24 | $215.7M | $129.0M | ||
| Q3 24 | $196.6M | $118.6M | ||
| Q2 24 | $198.6M | $120.3M | ||
| Q1 24 | $188.6M | $120.0M |
净利润OFIXPRPL
| Q4 25 | $-2.2M | $-3.2M | ||
| Q3 25 | $-22.8M | $-11.7M | ||
| Q2 25 | $-14.1M | $-17.3M | ||
| Q1 25 | $-53.1M | $-19.1M | ||
| Q4 24 | $-29.1M | $-8.5M | ||
| Q3 24 | $-27.4M | $-39.2M | ||
| Q2 24 | $-33.4M | $27.0K | ||
| Q1 24 | $-36.0M | $-50.2M |
毛利率OFIXPRPL
| Q4 25 | 71.1% | 41.9% | ||
| Q3 25 | 72.2% | 42.8% | ||
| Q2 25 | 68.7% | 35.9% | ||
| Q1 25 | 62.8% | 39.4% | ||
| Q4 24 | 69.0% | 42.9% | ||
| Q3 24 | 68.7% | 29.7% | ||
| Q2 24 | 67.8% | 40.7% | ||
| Q1 24 | 67.5% | 34.8% |
营业利润率OFIXPRPL
| Q4 25 | 0.2% | -1.6% | ||
| Q3 25 | -8.3% | -10.2% | ||
| Q2 25 | -7.9% | -13.5% | ||
| Q1 25 | -25.2% | -13.9% | ||
| Q4 24 | -5.3% | -6.0% | ||
| Q3 24 | -9.6% | -39.5% | ||
| Q2 24 | -12.5% | -12.1% | ||
| Q1 24 | -15.6% | -19.3% |
净利率OFIXPRPL
| Q4 25 | -1.0% | -2.3% | ||
| Q3 25 | -11.1% | -9.9% | ||
| Q2 25 | -6.9% | -16.5% | ||
| Q1 25 | -27.4% | -18.4% | ||
| Q4 24 | -13.5% | -6.6% | ||
| Q3 24 | -13.9% | -33.1% | ||
| Q2 24 | -16.8% | 0.0% | ||
| Q1 24 | -19.1% | -41.8% |
每股收益（稀释后）OFIXPRPL
| Q4 25 | $-0.05 | $0.03 | ||
| Q3 25 | $-0.57 | $0.11 | ||
| Q2 25 | $-0.36 | $0.16 | ||
| Q1 25 | $-1.35 | $0.18 | ||
| Q4 24 | $-0.76 | $0.08 | ||
| Q3 24 | $-0.71 | $0.36 | ||
| Q2 24 | $-0.88 | $0.00 | ||
| Q1 24 | $-0.95 | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | $450.0M | $-29.7M |
| 总资产 | $850.6M | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXPRPL
| Q4 25 | $82.0M | $24.3M | ||
| Q3 25 | $62.9M | $32.4M | ||
| Q2 25 | $65.6M | $34.2M | ||
| Q1 25 | $58.0M | $21.6M | ||
| Q4 24 | $83.2M | $29.0M | ||
| Q3 24 | $30.1M | $23.4M | ||
| Q2 24 | $26.4M | $23.4M | ||
| Q1 24 | $27.0M | $34.5M |
总债务OFIXPRPL
| Q4 25 | — | $126.7M | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | $70.7M | ||
| Q3 24 | $118.5M | $50.8M | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXPRPL
| Q4 25 | $450.0M | $-29.7M | ||
| Q3 25 | $442.5M | $-26.9M | ||
| Q2 25 | $458.3M | $-15.6M | ||
| Q1 25 | $458.3M | $1.3M | ||
| Q4 24 | $503.1M | $20.2M | ||
| Q3 24 | $525.9M | $28.0M | ||
| Q2 24 | $546.0M | $66.4M | ||
| Q1 24 | $570.3M | $65.5M |
总资产OFIXPRPL
| Q4 25 | $850.6M | $296.3M | ||
| Q3 25 | $832.6M | $302.1M | ||
| Q2 25 | $837.2M | $303.8M | ||
| Q1 25 | $823.1M | $293.8M | ||
| Q4 24 | $893.3M | $307.8M | ||
| Q3 24 | $867.9M | $309.3M | ||
| Q2 24 | $882.0M | $362.1M | ||
| Q1 24 | $906.0M | $382.1M |
负债/权益比OFIXPRPL
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | 3.50× | ||
| Q3 24 | 0.23× | 1.82× | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-7.8M |
| 自由现金流率自由现金流/营收 | 7.6% | -5.5% |
| 资本支出强度资本支出/营收 | 4.9% | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-41.9M |
8季度趋势，按日历期对齐
经营现金流OFIXPRPL
| Q4 25 | $27.7M | $-5.8M | ||
| Q3 25 | $12.4M | $-968.0K | ||
| Q2 25 | $11.6M | $-4.0M | ||
| Q1 25 | $-18.4M | $-23.1M | ||
| Q4 24 | $23.7M | $6.8M | ||
| Q3 24 | $11.7M | $1.1M | ||
| Q2 24 | $9.0M | $-8.9M | ||
| Q1 24 | $-18.6M | $-16.8M |
自由现金流OFIXPRPL
| Q4 25 | $16.8M | $-7.8M | ||
| Q3 25 | $2.5M | $-1.8M | ||
| Q2 25 | $4.5M | $-7.0M | ||
| Q1 25 | $-25.1M | $-25.3M | ||
| Q4 24 | $15.2M | $5.7M | ||
| Q3 24 | $6.3M | $101.0K | ||
| Q2 24 | $-360.0K | $-11.0M | ||
| Q1 24 | $-29.1M | $-19.9M |
自由现金流率OFIXPRPL
| Q4 25 | 7.6% | -5.5% | ||
| Q3 25 | 1.2% | -1.5% | ||
| Q2 25 | 2.2% | -6.6% | ||
| Q1 25 | -13.0% | -24.3% | ||
| Q4 24 | 7.0% | 4.4% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | -0.2% | -9.2% | ||
| Q1 24 | -15.4% | -16.5% |
资本支出强度OFIXPRPL
| Q4 25 | 4.9% | 1.4% | ||
| Q3 25 | 4.8% | 0.7% | ||
| Q2 25 | 3.5% | 2.8% | ||
| Q1 25 | 3.5% | 2.2% | ||
| Q4 24 | 4.0% | 0.8% | ||
| Q3 24 | 2.7% | 0.9% | ||
| Q2 24 | 4.7% | 1.7% | ||
| Q1 24 | 5.6% | 2.5% |
现金转化率OFIXPRPL
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -330.22× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
